File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1080/22221751.2023.2209201
- Scopus: eid_2-s2.0-85159759999
- Find via
Supplementary
Article: Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study
Title | Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study |
---|---|
Authors | |
Keywords | BNT162b2 CoronaVac COVID-19 Omicron waning vaccine effectiveness |
Issue Date | 18-May-2023 |
Publisher | Taylor and Francis Group |
Citation | Emerging Microbes & Infections, 2023, v. 12, n. 1 How to Cite? |
Abstract | Background: This study aims to evaluate waning effectiveness against severe and fatal COVID-19 with two to three doses of CoronaVac/BNT162b2, where data are limited. Methods: A case–control study included individuals aged ≥18 years, unvaccinated or received two to three doses of CoronaVac/BNT162b2, using electronic healthcare databases in Hong Kong. Those with first COVID-19-related hospitalization, severe complications, or mortality between 1 January and 15 August 2022 were defined as cases and matched with up-to-10 controls by age, sex, index date, and Charlson Comorbidity Index. Vaccine effectiveness (VE) against COVID-19-related outcomes was estimated at different time intervals from second and third-dose vaccination (0–13 up-to 210–240 days) using conditional logistic regression adjusted for comorbidities and medications. Results: By 211–240 days after second dose, VE against COVID-19-related hospitalization reduced to 46.6% (40.7–51.8%) for BNT162b2 and 36.2% (28.0–43.4%) for CoronaVac, and VE against COVID-19-related mortality were 73.8% (55.9–84.4%) and 76.6% (60.8–86.0%). After third dose, VE against COVID-19-related hospitalization decreased from 91.2% (89.5–92.6%) for BNT162b2 and 76.7% (73.7–79.4%) for CoronaVac at 0–13 days, to 67.1% (60.4–72.6%) and 51.3% (44.2–57.5%) at 91–120 days. VE against COVID-19-related mortality for BNT162b2 remained high from 0–13 days [98.2% (95.0–99.3%)] to 91–120 days [94.6% (77.7–98.7%)], and for CoronaVac reduced from 0–13 days [96.7% (93.2–98.4%)] to 91–120 days [86.4% (73.3–93.1%)]. Conclusions: Significant risk reduction against COVID-19-related hospitalization and mortality after CoronaVac or BNT162b2 vaccination was observed for >240 and >120 days after second and third doses compared to unvaccinated, despite significant waning over time. Timely administration of booster doses could provide higher levels of protection. |
Persistent Identifier | http://hdl.handle.net/10722/336560 |
ISSN | 2021 Impact Factor: 19.568 2020 SCImago Journal Rankings: 2.475 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yan, Vincent Ka Chun | - |
dc.contributor.author | Wan, Eric Yuk Fai | - |
dc.contributor.author | Ye, Xuxiao | - |
dc.contributor.author | Mok, Anna Hoi Ying | - |
dc.contributor.author | Lai, Francisco Tsz Tsun | - |
dc.contributor.author | Chui, Celine Sze Ling | - |
dc.contributor.author | Li, Xue | - |
dc.contributor.author | Wong, Carlos King Ho | - |
dc.contributor.author | Li, Philip Hei | - |
dc.contributor.author | Ma, Tiantian | - |
dc.contributor.author | Qin, Simon | - |
dc.contributor.author | Lau, Chak Sing | - |
dc.contributor.author | Wong, Ian Chi Kei | - |
dc.contributor.author | Chan, Esther Wai Yin | - |
dc.date.accessioned | 2024-02-16T10:31:40Z | - |
dc.date.available | 2024-02-16T10:31:40Z | - |
dc.date.issued | 2023-05-18 | - |
dc.identifier.citation | Emerging Microbes & Infections, 2023, v. 12, n. 1 | - |
dc.identifier.issn | 2222-1751 | - |
dc.identifier.uri | http://hdl.handle.net/10722/336560 | - |
dc.description.abstract | <p>Background: This study aims to evaluate waning effectiveness against severe and fatal COVID-19 with two to three doses of CoronaVac/BNT162b2, where data are limited. Methods: A case–control study included individuals aged ≥18 years, unvaccinated or received two to three doses of CoronaVac/BNT162b2, using electronic healthcare databases in Hong Kong. Those with first COVID-19-related hospitalization, severe complications, or mortality between 1 January and 15 August 2022 were defined as cases and matched with up-to-10 controls by age, sex, index date, and Charlson Comorbidity Index. Vaccine effectiveness (VE) against COVID-19-related outcomes was estimated at different time intervals from second and third-dose vaccination (0–13 up-to 210–240 days) using conditional logistic regression adjusted for comorbidities and medications. Results: By 211–240 days after second dose, VE against COVID-19-related hospitalization reduced to 46.6% (40.7–51.8%) for BNT162b2 and 36.2% (28.0–43.4%) for CoronaVac, and VE against COVID-19-related mortality were 73.8% (55.9–84.4%) and 76.6% (60.8–86.0%). After third dose, VE against COVID-19-related hospitalization decreased from 91.2% (89.5–92.6%) for BNT162b2 and 76.7% (73.7–79.4%) for CoronaVac at 0–13 days, to 67.1% (60.4–72.6%) and 51.3% (44.2–57.5%) at 91–120 days. VE against COVID-19-related mortality for BNT162b2 remained high from 0–13 days [98.2% (95.0–99.3%)] to 91–120 days [94.6% (77.7–98.7%)], and for CoronaVac reduced from 0–13 days [96.7% (93.2–98.4%)] to 91–120 days [86.4% (73.3–93.1%)]. Conclusions: Significant risk reduction against COVID-19-related hospitalization and mortality after CoronaVac or BNT162b2 vaccination was observed for >240 and >120 days after second and third doses compared to unvaccinated, despite significant waning over time. Timely administration of booster doses could provide higher levels of protection.</p> | - |
dc.language | eng | - |
dc.publisher | Taylor and Francis Group | - |
dc.relation.ispartof | Emerging Microbes & Infections | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | BNT162b2 | - |
dc.subject | CoronaVac | - |
dc.subject | COVID-19 | - |
dc.subject | Omicron | - |
dc.subject | waning vaccine effectiveness | - |
dc.title | Waning effectiveness against COVID-19-related hospitalization, severe complications, and mortality with two to three doses of CoronaVac and BNT162b2: a case-control study | - |
dc.type | Article | - |
dc.identifier.doi | 10.1080/22221751.2023.2209201 | - |
dc.identifier.scopus | eid_2-s2.0-85159759999 | - |
dc.identifier.volume | 12 | - |
dc.identifier.issue | 1 | - |
dc.identifier.eissn | 2222-1751 | - |
dc.identifier.issnl | 2222-1751 | - |